9W8.F IKONISYS EO 2
- Market cap
- EUR 21.2M
- P/E
- -
- P/B
- 1.15x
- ROE
- -22.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 9W8.F undervalued?
Graham numberThe Graham number of IKONISYS EO 2 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IKONISYS EO 2 fundamental analysis
No fundamental analysis for IKONISYS EO 2 yet.
IKONISYS EO 2 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IKONISYS EO 2
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that a…
Full company profileIKONISYS EO 2 financial statements
IKONISYS EO 2 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 365K | 617K | 449K | 1.02M | 1.39M |
| Gross Profit | 295K | 433K | 256K | 725K | 897K |
| Operating Income | -742K | -2.75M | -2.39M | -3.09M | -4.04M |
| EBITDA | - | -1.35M | -927K | -1.69M | -1.14M |
| Net Income | -571K | -2.45M | -2.27M | -3.24M | -4.20M |
| EPS | -0.06 | -0.26 | -0.23 | -0.29 | -0.27 |
| Balance Sheet | |||||
| Total Assets | 22.5M | 21.7M | 20.9M | 27.4M | 26.7M |
| Total Liabilities | 2.50M | 4.04M | 5.12M | 13.1M | 7.58M |
| Shareholders' Equity | 20.0M | 17.7M | 15.7M | 14.3M | 19.1M |
| Cash & Short-term Investments | 1.52M | 94.0K | 9.40K | 25.1K | 1.03M |
| Cash Flow | |||||
| Operating Cash Flow | -781K | -1.14M | -914K | -1.21M | -1.16M |
| Capital Expenditure | 576K | 875K | 542K | 37.9K | 258K |
| Free Cash Flow | -1.36M | -2.01M | -1.46M | -1.25M | -1.42M |
| Ratios | |||||
| ROE | -2.9% | -13.9% | -14.4% | -22.7% | -22.0% |
| ROA | -2.5% | -11.3% | -10.9% | -11.8% | -15.7% |
| Net Profit Margin | -156.5% | -396.9% | -505.5% | -317.3% | -302.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IKONISYS EO 2 dividends
IKONISYS EO 2 has not paid dividends in the last 5 fiscal years.
Who owns IKONISYS EO 2
- Insiders 17.79%
- Institutions 45.42%
- Public & others 36.79%
- Shares outstanding 15.8M
- Free float 7.18M
IKONISYS EO 2 company profile
- Company name
- IKONISYS EO 2
- Ticker
- 9W8.F
- ISIN
- FR00140048X2
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 15
- Fiscal year end
- December
- Address
- 62 rue de Caumartin, Paris, France, 75009
- Phone
- 33 39 348 901 9064
- Website
- ikonisys.com
About IKONISYS EO 2
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. In addition, it offers liquid biopsy/CTC bladder cancer detection and breast cancer early diagnostics products; CYTOfast vial solution for any type of cellular analysis; CYTOfast kit urine, a three day cytological urine test solution; CYTOfast PLUS, a liquid-phase processor that prepares thin-layer cytological samples from liquid-phase specimen; and Ikonisys intelligent application, a software designed to automatically quantify, qualify, and present cells for review and streamlining the diagnostic process. Ikonisys S.A. was incorporated in 2021 and is headquartered in Paris, France.
IKONISYS EO 2 management
4- Mr. Francesco TrisoliniChief Executive Officer
- Dr. Michael W. Kilpatrick Ph.D.Founder & CSO
- Mr. Alessandro MauriChief Financial Officer
- Mr. Jurgen SchipperSales Director